hsa-mir-361: Hsa-mir-361 is a specific microRNA (miRNA) that has been studied in various contexts. It has been included in cDNA synthesis and reverse transcription reactions using the TaqMan® MicroRNA Reverse Transcription Kit and specific RT primers [PMC7998231]. In paired tumor and normal samples, hsa-mir-361 showed lower absolute log fold change (LFC) compared to hsa-miR-16-5p [PMC8186776]. Hsa-mir-361 has not been extensively investigated in the context of common miRNAs, and further research is needed to determine its pan-cancer prognostic potential [PMC6602415]. It has been found to be upregulated in the third trimester of pregnancy, along with other miRNAs such as hsa-miR-let7e, hsa-miR-107, and hsa-miR-370 [PMC9700700]. In the first trimester of pregnancy, hsa-mir-361 was significantly upregulated in patients with gestational diabetes mellitus (GDM) [PMC9700700]. Hsa-mir-361 has also been implicated in various cancer types, including intestinal type T1N0M0 and T1N1M0 tumors [PMC4496000]. Additionally, it has been shown to play a role in cell fusion capacity enhancement and disease progression prediction [PMC4325962] [PMC8706837]. In breast cancer studies, hsa-mir-361 expression was found to be downregulated in docetaxel-resistant cells but upregulated in metastatic tumors. It also targets FGFR1 and MMP-1 genes involved in glycolysis inhibition and invasion inhibition [PMC6208346]. Furthermore, it regulates genes involved in the VEGF signaling pathway as well as genes involved in the TGF-beta signaling pathway [PMC7955132].
Sequence features are shown above as colored rectangles. Zoom in and click to view details, or Reset
View annotations in different species by clicking on species names.
Scroll around to explore the entire tree. Click tree nodes to collapse or expand them. Hover over taxon names to display additional information.